PDCD1 and neoplasm: In conjunction with anti-PD-1, with a stable body weight (Supplementary Figure S6), APE-3 and APE-4 were effective in suppressing tumor growth in the B16-OVA subcutaneous tumor model and enhancing mouse survival, while APE-2 showed a suboptimal tumor regression and survival (Figure 9b,c).